Bio-Path (BPTH) Trading 2.2% Higher

Bio-Path Holdings Inc (NASDAQ:BPTH) traded up 2.2% on Tuesday . The company traded as high as $0.20 and last traded at $0.20. 635,533 shares were traded during mid-day trading, a decline of 26% from the average session volume of 853,456 shares. The stock had previously closed at $0.20.

A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Bio-Path from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright restated a “buy” rating and issued a $1.50 price objective (down from $4.50) on shares of Bio-Path in a report on Monday, November 13th. Finally, reduced their price objective on shares of Bio-Path from $4.50 to $1.50 and set a “buy” rating on the stock in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $1.67.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.02). sell-side analysts forecast that Bio-Path Holdings Inc will post -0.08 EPS for the current year.

An institutional investor recently raised its position in Bio-Path stock. Sabby Management LLC increased its stake in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) by 73.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,190,886 shares of the company’s stock after acquiring an additional 503,488 shares during the quarter. Sabby Management LLC owned about 1.19% of Bio-Path worth $462,000 at the end of the most recent quarter. 9.31% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit